# Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection

> **NCT02836925** · PHASE2 · COMPLETED · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 40 (actual)

## Conditions studied

- Indolent B-cell Lymphoma
- Hepatitis C

## Interventions

- **DRUG:** Ledipasvir+Sofosbuvir
- **DRUG:** Sofosbuvir+Velpatasvir

## Key facts

- **NCT ID:** NCT02836925
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2020-02
- **Final completion:** 2022-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02836925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02836925, "Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02836925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*